Abbott Laboratories reported robust first-quarter performance with broad-based growth across Established Pharmaceuticals and Diagnostic segments, while Nutritional Products experienced headwinds. The company advanced its portfolio expansion through the pending acquisition of Exact Sciences, enhancing its diagnostics presence. Operational efficiencies and a refreshed incentive stock program support ongoing margin improvement efforts amid industry pricing pressures. Key risks include regulatory scrutiny on infant formula litigation and acquisition integration challenges.